(PLOS) Structure-based drug design revealed that a compound previously investigated for the treatment of head-and-neck cancer could function as a lead compound for the development of drugs to treat hepatitis A virus infection, according to a study publishing April 30, 2019 in the open-access journal PLOS Biology by Dan Su of Sichuan University, Zihe Rao of Tsinghua University, Xiangxi Wang of the Chinese Academy of Sciences, and colleagues.
from EurekAlert! - Technology, Engineering and Computer Science http://bit.ly/2WennaY
Wednesday, May 1, 2019
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment